references
- Kerem E, Conway S, Elbom S, Heijerman. Standars of care for patients with cystic fibrosis: a European consensus. J Cyst Fi-bros 2005; 4 (1): 7–26.
- Smyth AR, Tan KH. Once-daily versus multiple-daily dos-ing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev. 2006 Jul 19; 3: CD002009.
- Smyth A, Tan KH, Hyman-Taylor P, Mulheran M, Lewis S, Stableforth D, Prof Knox A. Once versus three-times daily regi-mens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis-the TOPIC study: a randomised controlled trial. Lancet 2005; 365: 573–8.
- Mulheran M, Degg C, Burr S, Morgan DW, Stableforth DE. Occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated high-dose aminoglycoside therapy. Antimi-crob Agents Chemother 2001; 45: 2502–2509.
- Mulheran M, Hyman-Taylor P, Tan KH, Lewis S, Stable-forth DE, Knox A, Smyth A. Absence of cochleotoxicity meas-ured by standard and high-frequency pure tone audiometry in a trial of once versus three-times-daily tobramycin in cystic fibrosis patients. Antimicrob Agents Chemother 2006; 50: 2293–2299.
- Bertenshaw C, Watson A, Lewis S, Choonara I, McGaw J, Smyth A. A case control study of acute renal failure in cystic fi-brosis patients in the United Kingdom. Pediat Pulmonol 2007; Suppl 30: 321-322.
- Al-Aloul M, Jackson M, Bell G, Ledson M, Walshaw M. Comparison of methods of assessment of renal function in cys-tic fibrosis patients. J Cyst Fibros 2007; 6: 41–47.
- Chambers HF, Sande MA. Antimicrobial agents - The aminoglycosides. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman Gilman A. Goodman & Gilman's The pharmacological basis of therapeutics. 9th ed. New York: McGraw Hill. 1996: 1103-1121.
- Aminimaniziani A, Beringer PM, Kang J, Tsang L, Jelliffe RW, Shapiro BJ. Distribution and elimination of tobramycin ad-ministered in single or multiple daily doses in adult patients with cystic fibrosis. JAC 2002; 50: 553–559.
- Coulthard KP, Peckham DG, Conway SP, Smith CA, Bell J, Turnidge J. Therapeutic drug monitoring of once daily to-bramycin in cystic fibrosis-caution with trough concentrations. J Cyst Fibros 2007; 6: 125–130.
- Tjon JA; Murphy L, Seto W, Atenafu E, Wong C, Dekker A, Bitnun S, Waters V, Yau Y, Solomon M, Ratjen F. Clinical evaluation of once-daily tobramycin dosing guidelines in paedi-atric patients with cystic fibrosis. Pediat Pulmonol 2007; Suppl 30: 327-328.
- Tan KH, Mulheran M, Knox A. J, Smyth A. Aminoglyco-side prescribing and surveillance in cystic fibrosis. Am J Respir Crit Care Med 2003; 167: 819–823.